oncology

Britain's National Health Service (NHS) will begin the world's largest trial of Grail Inc's flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear. The Galleri test checks for the earliest signs of cancer in the...

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therapy engineered to target MAGE-A4 positive tumors and to express a CD8α co-receptor...

Wedbush initiated coverage of Tango Therapeutics Inc (NASDAQ: TNGX) with an Outperform rating and a $12 price target.  Analyst Robert Driscoll believes Tango's unique synthetic lethality approach is differentiated.  Furthermore, he expects Tango to leverage this...

Illumina Inc (NASDAQ: ILMN) and Merck & Co Inc (NYSE: MRK) provided more details on their partnership to develop and commercialize tests that gauge genetic mutations involved in homologous recombination deficiency (HRD) and identify best responders to PARP inhibitors....

Citius Pharmaceuticals Inc (NASDAQ: CTXR) has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-diphtheria toxin fusion protein. In March 2016, Dr. Reddy's had acquired the exclusive global rights,...

The FDA has granted a new 510(k) clearance to RenovoRx Inc's (NASDAQ: RNXT) RenovoCath Delivery System.  The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem.  The drug/device combination used in RenovoRx'...

Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's foralumab. The companies plan to explore the fully human anti-CD3 monoclonal antibody as an agent to induce tolerance of...

Innovent Biologics Inc (OTC: IVBIY) and Bolt Biotherapeutics Inc (NASDAQ: BOLT) have entered into a drug research and development collaboration for oncology candidates. The agreement covers three anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates. The Boltbody ISAC...

ADC Therapeutics SA (NYSE: ADCT) has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million. ADC Therapeutics will receive $225 million upon closing, with an additional $100 million in potential near-term milestone payments...

Rafael Pharmaceuticals Inc (NYSE: RFL) has completed a Phase 1b trial of CPI-613 (devimistat) combined with gemcitabine and cisplatin in patients with biliary tract cancer.  In collaboration with Michigan Medicine, the Phase 1b study consisted of a multicenter trial of...

Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the study is unlikely to meet its goal of improving overall survival. The INTR@PID BTC 055 trial examined the drug as a first-...

Trading of Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock was halted thrice during the early morning session. No company-specific reports are driving up the stock price today, so it appears there are external factors at play. Discussions about Sonnet have floated on...

Adagene Inc (NASDAQ: ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck's Keytruda (...

Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented partnership builds on the ongoing collaboration and license agreement to discover and develop mono-specific and multi-...

The FDA on Friday approved Merck & Co Inc's (NYSE: MRK) belzutifan for patients with the rare disorder known as von Hippel-Lindau (VHL) disease.  VHL is a rare genetic disease that causes tumors and cysts to grow throughout the body. Belzutifan was one of the most...